FDA's final and draft nanotechnology guidance documents: No big surprises

被引：0

|

作者：

机构：

来源：

Nanotechnol. Law Bus. | / 1卷 / 54-58期

关键词：

761; Nanotechnology;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

收藏

相关论文

共 50 条

[41] Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer's disease
Harrison, John E.
ALZHEIMERS RESEARCH & THERAPY, 2018, 10
[42] Cognition comes of age: comments on the new FDA draft guidance for early Alzheimer’s disease
John E. Harrison
Alzheimer's Research & Therapy, 10
[43] FDA's Evolving Approach to Nanotechnology
Monica, John C., Jr.
FOOD AND DRUG LAW JOURNAL, 2012, 67 (04) : 405 - 411
[44] FDA draft guidance to improve clinical trial diversity: Opportunities for pharmacoepidemiology
Russell, Elizabeth S.
Aubrun, Elodie
Moga, Daniela C.
Guedes, Sandra
Camelo Castillo, Wendy
Hardy, Janet R.
Cole, J. Alexander
Jagun, Oladayo
JOURNAL OF CLINICAL AND TRANSLATIONAL SCIENCE, 2023, 7 (01)
[45] FDA releases tissue-agnostic cancer drug draft guidance
Asher Mullard
Nature Reviews Drug Discovery, 2022, 21 : 868 - 868
[46] FDA issues draft guidance on development of abuse-deterrent opioids
Reactions Weekly, 2013, 1435 (1) : 4 - 4
[47] FDA releases tissue-agnostic cancer drug draft guidance
Mullard, Asher
NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (12) : 868 - 868
[48] FDA draft guidance on benefit-risk assessments for NDAs and BLAs
Reactions Weekly, 2021, 1876 (1) : 1 - 1
[49] The FDA’s latest draft guidance on accelerated approvals — one step forward, two steps back?
David J. Benjamin
Mark P. Lythgoe
Nature Reviews Clinical Oncology, 2023, 20 : 577 - 578
[50] The FDA's latest draft guidance on accelerated approvals - one step forward, two steps back?
Benjamin, David J.
Lythgoe, Mark P.
NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (09) : 577 - 578

← 1 2 3 4 5 →